Duchenne muscular dystrophy treatments see regulatory and clinical shifts

Developments in the treatment of Duchenne muscular dystrophy (DMD) are progressing through new therapeutic approaches and regulatory shifts. Capricor Therapeutics has announced it will amend its FDA filing for the cell therapy deramiocel. The company is pivoting from a focus on heart disease to a narrower indication centered on upper limb skeletal muscle function. This change follows data from the Phase 3 HOPE-3 trial, which showed a 4.55 percent mean difference in the slowing of muscle function decline. Consequently, the FDA is expected to extend the current decision deadline of August 22, 2026.

In parallel, the treatment landscape is expanding to include therapies that target secondary pathologies of the disease. Givinostat, an HDAC inhibitor developed by Italfarmaco S.p.A., is moving toward conditional marketing authorization in the European Union. Unlike therapies focused on dystrophin replacement, givinostat aims to mitigate the inflammatory and fibrotic processes that drive muscle degeneration. Clinical data suggests it can reduce the progression of motor function decline in ambulant patients when used as an add-on to standard glucocorticoid treatments.